20/20 Biolabs Inc Financials
This page shows 20/20 Biolabs Inc (AIDX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of 20/20 Biolabs Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
20/20 Biolabs Inc has an operating margin of -162.9%, meaning the company retains $-163 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -324.0% the prior year.
20/20 Biolabs Inc's revenue surged 16.7% year-over-year to $2.0M, reflecting rapid business expansion. This strong growth earns a score of 61/100.
20/20 Biolabs Inc carries a low D/E ratio of -216.21, meaning only $-216.21 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 74/100, indicating a strong balance sheet with room for future borrowing.
20/20 Biolabs Inc's current ratio of 0.60 is below the typical benchmark, resulting in a score of 6/100. This tight liquidity could limit financial flexibility if cash inflows slow.
20/20 Biolabs Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, 20/20 Biolabs Inc generates $0.51 in operating cash flow (-$1.9M OCF vs -$3.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
20/20 Biolabs Inc earns $-21.3 in operating income for every $1 of interest expense (-$3.3M vs $156K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
20/20 Biolabs Inc generated $2.0M in revenue in fiscal year 2025. This represents an increase of 16.7% from the prior year.
20/20 Biolabs Inc's EBITDA was -$3.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 41.2% from the prior year.
20/20 Biolabs Inc reported -$3.7M in net income in fiscal year 2025. This represents an increase of 32.7% from the prior year.
20/20 Biolabs Inc earned $-0.76 per diluted share (EPS) in fiscal year 2025. This represents an increase of 34.5% from the prior year.
Cash & Balance Sheet
20/20 Biolabs Inc held $1.0M in cash against $0 in long-term debt as of fiscal year 2025.
20/20 Biolabs Inc had 5M shares outstanding in fiscal year 2025. This represents an increase of 12.8% from the prior year.
Margins & Returns
20/20 Biolabs Inc's gross margin was 29.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 9.0 percentage points from the prior year.
20/20 Biolabs Inc's operating margin was -162.9% in fiscal year 2025, reflecting core business profitability. This is up 161.1 percentage points from the prior year.
20/20 Biolabs Inc's net profit margin was -182.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 134.0 percentage points from the prior year.
Capital Allocation
20/20 Biolabs Inc invested $593K in research and development in fiscal year 2025. This represents a decrease of 53.0% from the prior year.
AIDX Income Statement
| Metric | Q4'25 | Q4'24 |
|---|---|---|
| Revenue | N/A | N/A |
| Cost of Revenue | N/A | N/A |
| Gross Profit | N/A | N/A |
| R&D Expenses | N/A | N/A |
| SG&A Expenses | N/A | N/A |
| Operating Income | N/A | N/A |
| Interest Expense | N/A | N/A |
| Income Tax | N/A | N/A |
| Net Income | N/A | N/A |
| EPS (Diluted) | N/A | N/A |
AIDX Balance Sheet
| Metric | Q4'25 | Q4'24 |
|---|---|---|
| Total Assets | $4.1M+15.4% | $3.6M |
| Current Assets | $1.5M-27.7% | $2.0M |
| Cash & Equivalents | $1.0M-42.5% | $1.8M |
| Inventory | $116K+146.4% | $47K |
| Accounts Receivable | $200K+47.8% | $135K |
| Goodwill | N/A | N/A |
| Total Liabilities | $4.2M+99.9% | $2.1M |
| Current Liabilities | $2.5M+81.8% | $1.4M |
| Long-Term Debt | N/A | N/A |
| Total Equity | -$19K-101.3% | $1.5M |
| Retained Earnings | -$33.2M-12.7% | -$29.5M |
AIDX Cash Flow Statement
| Metric | Q4'25 | Q4'24 |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Investing Cash Flow | N/A | N/A |
| Financing Cash Flow | N/A | N/A |
| Dividends Paid | N/A | N/A |
| Share Buybacks | N/A | N/A |
AIDX Financial Ratios
| Metric | Q4'25 | Q4'24 |
|---|---|---|
| Gross Margin | N/A | N/A |
| Operating Margin | N/A | N/A |
| Net Margin | N/A | N/A |
| Return on Equity | N/A | N/A |
| Return on Assets | N/A | N/A |
| Current Ratio | 0.60-0.9 | 1.50 |
| Debt-to-Equity | -216.21-217.6 | 1.38 |
| FCF Margin | N/A | N/A |
Note: Shareholder equity is negative (-$19K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.60), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Frequently Asked Questions
What is 20/20 Biolabs Inc's annual revenue?
20/20 Biolabs Inc (AIDX) reported $2.0M in total revenue for fiscal year 2025. This represents a 16.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is 20/20 Biolabs Inc's revenue growing?
20/20 Biolabs Inc (AIDX) revenue grew by 16.7% year-over-year, from $1.8M to $2.0M in fiscal year 2025.
Is 20/20 Biolabs Inc profitable?
No, 20/20 Biolabs Inc (AIDX) reported a net income of -$3.7M in fiscal year 2025, with a net profit margin of -182.8%.
What is 20/20 Biolabs Inc's EBITDA?
20/20 Biolabs Inc (AIDX) had EBITDA of -$3.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is 20/20 Biolabs Inc's gross margin?
20/20 Biolabs Inc (AIDX) had a gross margin of 29.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is 20/20 Biolabs Inc's operating margin?
20/20 Biolabs Inc (AIDX) had an operating margin of -162.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is 20/20 Biolabs Inc's net profit margin?
20/20 Biolabs Inc (AIDX) had a net profit margin of -182.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is 20/20 Biolabs Inc's operating cash flow?
20/20 Biolabs Inc (AIDX) generated -$1.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are 20/20 Biolabs Inc's total assets?
20/20 Biolabs Inc (AIDX) had $4.1M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does 20/20 Biolabs Inc spend on research and development?
20/20 Biolabs Inc (AIDX) invested $593K in research and development during fiscal year 2025.
What is 20/20 Biolabs Inc's current ratio?
20/20 Biolabs Inc (AIDX) had a current ratio of 0.60 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is 20/20 Biolabs Inc's debt-to-equity ratio?
20/20 Biolabs Inc (AIDX) had a debt-to-equity ratio of -216.21 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is 20/20 Biolabs Inc's return on assets (ROA)?
20/20 Biolabs Inc (AIDX) had a return on assets of -90.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is 20/20 Biolabs Inc's cash runway?
Based on fiscal year 2025 data, 20/20 Biolabs Inc (AIDX) had $1.0M in cash against an annual operating cash burn of $1.9M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is 20/20 Biolabs Inc's debt-to-equity ratio negative or unusual?
20/20 Biolabs Inc (AIDX) has negative shareholder equity of -$19K as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is 20/20 Biolabs Inc's Piotroski F-Score?
20/20 Biolabs Inc (AIDX) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are 20/20 Biolabs Inc's earnings high quality?
20/20 Biolabs Inc (AIDX) has an earnings quality ratio of 0.51x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can 20/20 Biolabs Inc cover its interest payments?
20/20 Biolabs Inc (AIDX) has an interest coverage ratio of -21.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is 20/20 Biolabs Inc?
20/20 Biolabs Inc (AIDX) scores 24 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.